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ABSTRACT 
 
 
Pulmonary Arterial Hypertension (PAH) is a devastating disease characterized by a 
persistent increase in pulmonary arterial resistance. Endothelin is a hormone involved in 
maintaining vasoconstriction, but the enzymes and proteins involved in its signaling pathway are 
not fully known. Understanding the endothelin-B (ETB) signaling pathway is crucial for the 
development of a more specific endothelin-targeted therapy for PAH.  Therefore, the objective of 
this project was to identify mediators utilized by the ETB receptor and help determine their 
function in the regulation of ATP neurotransmitter release.  In rat PC12 cells differentiated by 
neuronal growth factor, the inhibition of PLC was shown to reduce ETB-mediated ATP release. 
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BACKGROUND 
 
Pulmonary Arterial Hypertension 
 Pulmonary Arterial Hypertension (PAH) is a progressive, symptomatic, and ultimately a 
fatal disorder that elevates the blood pressure in the pulmonary arteries, putting the patients’ 
median life expectancy at only 2.8 years (McGoon & Garvan, 2009).  Although treatment for the 
disease has improved in the last decade, our limited understanding of the disease pathogenesis 
impedes the achievement of optimal outcomes. The pathobiology of PAH is composed of many 
factors, including increased pressure in the arteries that connect the lung to the heart. As a result, 
the right side of the heart has to work harder to pump blood through the lungs. As the disease 
progresses, morphological changes to the pulmonary vessel wall and coagulation increase 
pulmonary vascular resistance (McGoon & Garvan, 2009). 
 PAH was first described over 100 years ago in a patient with right-heart failure that was 
diagnosed with syphilitic pulmonary arteritis.   Clinically PAH is defined simply as raised blood 
pressure in the pulmonary arteries. Normal pressure ranges from 15 to 25 mm Hg systolic, and 8 
to 15 mm Hg diastolic, with mean pressure between 10 and 20 mm Hg.  When mean pulmonary 
artery pressure increases to 25 mm Hg or higher, with a pulmonary capillary wedge pressure of 
15 mm Hg or less, then the patient is diagnosed with PAH (Gaine & Rubin, 1998).  
 
Pathophysiology of PAH 
 PAH, regardless of the cause, leads to the enlargement of the right ventricle of the heart 
as it attempts to compensate for abnormally high pressure in the pulmonary arteries.  If the right 
ventricle cannot enlarge, then the pressure will increase in the right atrium and systemic venous 
system.  Eventually symptoms of right-sided heart failure, or cor pulmonale, are manifested in 
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the patient. Patients often complain about fatigue, this is because the right ventricle cannot pump 
enough blood, which is deoxygenated, into the lungs to be oxygenated. The bone marrow 
attempts to compensate for the lack of oxygen by stepping up red blood cell production. 
Unfortunately this leads to polycythemia, a thickening of the blood. This puts even more stress 
on the heart since viscous blood is harder to pump, and clotting is more likely (Holcomb, 2005).  
 Signs and symptoms associated with PAH include reduced oxygenation, decreased 
cardiac output, and an inability to increase cardiac output, which leads to symptoms mimicking 
heart failure, such as shortness of breath, fatigue, and syncope (fainting). During increased 
activity these symptoms may increase and lead to angina-like chest pains. Direct signs of right 
ventricular failure include peripheral edema, hepatomegaly, tricuspid regurgitation, an S3 heart 
sound, prominent right ventricular impulse and jugular vein distension.  Diagnosis is usually 
reached by analyzing a patient's medical history for congenital heart disease or the use of banned 
weight-reduction medication (Holcomb, 2005).  
 
PAH Classification 
 Patients with PAH are divided into 4 classes of degree of severity.  Class I patients have 
no limitation of physical activity, and ordinary activity does not cause fatigue, chest pain, or near 
syncope. Class II patients have slight limitation of physical activity.  Patients are comfortable at 
rest, but ordinary physical activity causes fatigue, chest pain, or near syncope.  Class III patients 
have limitations to physical activity.  These patients are comfortable at rest, but less-than-
ordinary physical activity causes fatigue, chest pain, and near syncope.  Class IV patients cannot 
do any physical activity without symptoms. When at rest, these patients may be fatigued, and any 
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physical activity leads to discomfort.  These patients show signs of right-sided heart failure 
(Cipla Doc, 2000). 
 In July of 2004, the American College of Chest Physicians reclassified PAH on the basis 
of etiology.  Primary PAH became idiopathic PAH, or familial PAH if the cause is supported 
genetically.  Idiopathic PAH occurs predominantly among young adults who are probably 
predisposed to the disorder. Other classifications are related to specific etiologies. PAH cases 
caused by underlying disease such as HIV or toxicity are much more common. Prior to 
widespread use of the weight-reduction drugs fenfluramine and dexfenfluramine in 1967, PAH 
was a relatively rare disease afflicting only 1-2 cases per million people annually. The rate of 
prevalence rose to 25-50 per million annually following the widespread use of these appetite 
suppressants.  Although these drugs were banned from the market in 1997, PAH caused by these 
toxic drugs did not go away because of an illegal black-market. Also because of the prevalence 
of HIV the incidence rate of PAH has not been reduced (Holcomb, 2005). 
  
Cellular Pathways of PAH 
 Various cellular pathway abnormalities are associated with the development and 
progression of PAH.  Regardless of the cause all PAH patients have abnormal pulmonary 
endothelium function. The pulmonary endothelium's purpose is to maintain low pulmonary 
vascular resistance.  In order to perform its job correctly, a balanced production of vasodilators 
(in this case prostacyclin and nitric oxide) and vasoconstrictors (such as endothelin-1, 
thromboxan A2, and serotonin) must be maintained.  Therefore, patients with PAH are 
characterized with a decreased concentration of prostacyclin and nitric oxide, while the 
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production of thromboxan A2 and endothelin-1 increases  (Yildiz, 2009, p. 9).  An increasing 
concentration of endothelin is associated with the progression of PAH.   
 However, endothelial cell dysfunction is just one of the causes of the disease.  PAH can 
also be caused by other factors that lead to dysfunction of pulmonary circulation, such as 
activation of adventitial fibroblasts, or the alteration of extracellular matrix components.  Factors 
that trigger the initiation of the disease are unknown, but once the disease is triggered the 
consequences include vasoconstriction, vascular smooth muscle cell and endothelial cell 
proliferation, and remodeling and thrombosis that cause the blood vessel to become narrower. As 
the disease progress, more collagen and smooth muscle cells are synthesized in the pulmonary 
artery in response to pulmonary artery pressure experienced by endothelial cells (Yildiz, 2009, p. 
10). These changes in the vascular structure of the pulmonary artery lead to loss of function and 
eventually right ventricular dysfunction. 
 In 2000, a gene on chromosome 2 that encodes for bone morphogenetic protein receptor 
II (BMPR2) was found to be associated with familial pulmonary arterial hypertension (FPAH). 
Mutations in BMPR2 occur in 50% of patients with familial PAH, while 25% of patients with 
idiopathic PAH display this mutation (Holcomb, 2005).  However, fewer than 20% of the 
individuals carrying the mutated version of this gene develop FPAH.  About 65% of families 
with familial PAH have exonic or intronic allelic variants in the BMPR2 gene, and they are 
transmitted in an autosomal dominant manner. Also some 10% of sporadic cases of IPAH 
involve isolated exonic allelic variants of the BMPR2 gene (McGoon & Garvan, 2009, p. 1). The 
reason why BMPR2 mutates is still unknown, but researchers believe environmental stimuli or 
other genes interfering with BMPR2 may lead to its mutation (Gaine & Rubin, 1998, p. 2). The 
mutated allelic variants of BMPR2 cause amino acid changes in the BMPR2 protein that 
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interrupt signal transduction during the process of pulmonary vascular smooth muscle cell 
apoptosis, thus promoting cellular proliferation (McGoon & Garvan, 2009). 
 
PAH Treatments 
 Treating PAH starts with removing any stressors or drugs that give rise to or exacerbates 
the disease. For example, the weight loss drugs fenfluramine and dexfenfluramine are known to 
cause PAH, so if a patient was taking one of these they are discontinued.  PAH is not curable, so 
treatment is aimed at reducing pressure, removing excess fluid, and reducing the risk of clotting. 
The usual drug cocktail consists of vasodilators, anticoagulants, and careful use of diuretics. 
Supplemental oxygen is also advisable if blood oxygen saturation reaches below 90%. Patients 
with sleep apnea and PAH should use a Continuous Positive Airway Pressure device, as this 
treatment decreases pulmonary artery pressure. Modern pharmaceutical treatment for PAH 
includes calcium channel blockers, prostacyclin analogues, endothelin receptor antagonists, 
phosphodiesterase inhibitors, and thromboxane inhibitors, all of which dilate the pulmonary 
artery, and thus may stop the progression of PAH by maintaining endothelial integrity (Holcomb, 
2005). 
 The first vasodilators used to treat PAH were calcium channel blockers.  This approach 
only works with about 20% of patients with idiopathic PAH, and does not seem to help other 
types of PAH.  Also patients with cor pulmonale must avoid calcium channel blockers because 
they decrease myocardial contractility and may thus induce heart failure. High doses of 
dihydropyridine calcium channel blockers are required for adequate dilation of the pulmonary 
arteries (Robbins, 2006).  Initial administration must be done in a clinical setting to monitor for 
adverse reactions. An acute vasoreactivity test is recommended for calcium channel blocker 
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candidates. This test uses known short-acting vasodilators such as intravenous adenosine or 
epoprostenol or inhaled nitric oxide. About 25% of patients with PAH have a positive response 
to these short acting drugs, which is defined as a decrease in pulmonary arterial pressure of 10 to 
40 mm Hg, and an increased or unchanged cardiac output (Mehta, 2003). Those with a negative 
response usually have a worse prognosis. Another side affect of calcium channel blockers is 
edema in the lower extremities, although this is usually controlled by diuretics (Rich, 2000, p. 3). 
 Only 30% of patients lived past 3 years after diagnosis before the development of 
vasodilators and endothelin receptor antagonists. These new drugs dilate the pulmonary arteries, 
reducing pressure and thus increasing life expectancy. Epoprostenol, a prostacyclin approved by 
the FDA in 1995, is administered via continuous I.V. infusion through a long-term central venous 
access device by a portable battery operated pump. This drug is a candidate for Class III and IV 
patients who are not candidates for calcium channel blocker therapy.  Treprostinil, an analogue 
of prostacyclin, is given as a continuous subcutaneous infusion. It was approved in 2002 and has 
boosted the survival rates to over 65%. Again the guidelines stipulate that this drug should only 
be given to Class III and Class IV patients that are not candidates for calcium channel blockers. 
Iloprost is a newer drug similar to prostacyclin that is inhaled, avoiding all the risks associated 
with a continuously administered injectable. It is only given along the same guidelines as 
Epoprostenol (Holcomb, 2005). 
 In 2001, Bosentan, an endothelin receptor antagonist, became the first oral drug for PAH 
approved by the FDA.  Only used for Class III and IV patients, this drug may stop progression of 
PAH or may even reverse it.  Future research focuses on finding better pulmonary vasodilators 
that have a convenient admission route while also not causing systemic hypotension (Holcomb, 
2005). 
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Endothelin 
 An increasing concentration of endothelin is associated with the progression of PAH. As 
PAH progresses, changes in the vascular structure become apparent, such as inflammation, 
vasoconstriction, cell proliferation, hypertrophy, and the formation of plexiform lesions. These 
changes in the vascular structure of the pulmonary artery lead to loss of function and eventually 
right ventricular dysfunction (Goraca, 2002).  Hickey discovered an unknown factor produced in 
the endothelium that causes smooth muscles to contract (Galie et al., 2004).  By 1988, 
Yanagisawa isolated and identified this factor from pig arterial endothelial cells, and called it 
endothelin-1 (ET-1) (Galie et al., 2004).   
 Endothelin-1 is a 21 amino acid peptide with a molecular weight of 2492 daltons 
(Figure-1). There are currently 3 known isomers (ET-1, ET-2, and ET-3).  Endothelin has two 
disulfide bonds, one between cysteine amino acids 1 and 15, and another between 3 and 11.  The 
presence of these disulfide bonds is critical because it contributes to the biological activity of ET 
(Goraca, 2002).  All three isoforms share a common structure that is characterized by the 
existence of two disulfide bridges, a loop configuration, and an active site at the C terminus 
according to figure 1 (Bouallegue & Srivastava, 2007). 
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Figure 1:  Diagram of Endothelin Primary Structure and the Factors 
Controlling its Regulation (Piuhola, 2002). 
 
 Many mammalian species, including humans, carry genes encoding endothelin.  Three 
separate genes encode ET-1, ET-2, and ET-3, but the resultant proteins are all made up of 21 
amino acids with two disulfide bonds. The isomers ET-1 and ET-3 differ in 6 out of the 21 
amino acid positions. This causes each endothelin variant to have different affinities toward 
different receptors. For example ET-1 has a higher affinity for the receptor ETA compared to 
ETB. All endothelins have equal affinity for the ETB receptor.  ET-1 is mostly expressed in 
endothelial cells, but it is also found in vascular and airway smooth muscle cells, leukocytes, 
marcophages, cardiomyocytes, and mesangial cells.  ET-2 on the other hand is mostly found in 
the kidney and intestine.  ET-3 is mostly expressed in the brain. This differing level of 
expression for each endothelin and its receptor is the cause behind the different regulatory 
mechanisms of each organ or tissue system (Miyauchi & Masaki, 1999). 
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 There are many factors involved in the up regulation or down regulation of endothelin, 
among them, shear stress, extreme pH, oxidized low-density lipoprotein, glucose, insulin, 
angiotensin II, catecholamines, growth factors, nitric oxide, and prostacyclin (Ergul, 2002). 
 An elevated level of ET-1 is seen in patients with acute myocardial infarction, 
hypertension, and heart failure. Because of these observations, ET-1 has become associated with 
the pathophysiology of these disease states.  ET-1 mediates its effects through two distinct 
heptahelical G-protein-coupled receptors, the endothelin ETA and endothelin ETB receptors 
(Kanai & Hasegawa, 2004). On the smooth muscles of the vascular bed, both receptors are found 
and both are responsible for mediating contraction. On the other hand, the endothelin ETB 
receptors on endothelial cells are responsible for mediating vasodilatative factors such as nitric 
oxide (NO) and prostacyclin (Masaki et al., 1999). 
 Developmental studies of endothelin-deficient and endothelin-receptor-deficient mice 
have shown the important role of endothelin during embryonic development. ET-1-deficient 
mice soon die after birth because of abnormal development of craniofacial and cardiac muscles 
(Miyauchi & Masaki, 1999). 
 
Endothelin Signal Transduction 
 Three signaling pathways are disturbed in patients with PAH: the nitric oxide pathway, 
the prostacyclin pathway, and the endothelin pathway (see figure 2).  We will mainly focus on 
the endothelin pathway (Figure-2), since it is the major participant in the pathogenesis of PAH 
(McGoon & Garvan, 2009, p. 192). 
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Figure 2: Endothelin-1 Signal Transduction.  Shown are the molecular mechanisms for 
vasoconstriction mediated by endothelin-1 binding to endothelin ETA and ETB receptors. NSCC: 
non-selective cation channel, Kch: calcium sensitive potassium channel, PLC: phospholipase C, 
VOC: voltage operated calcium channel, IP3: inositol tris-phosphate, SR: sarcoplasmic reticulum, 
+ potentiate, - inhibition (Masaki et al., 1999). 
 
 Both endothelin ETA and ETB receptors bind to G-proteins on the cytoplasmic side of the 
membrane. These G-proteins are then linked to adenylyl cyclase which dephophorylates ATP 
into cyclic AMP (cAMP). According to figure 2 Gs-protein (stimulatory G-protein) binds to the 
ETA receptor, and Gi-protein (inhibitory G-protein) binds to the ETB receptor. The activation of 
ETA thus releases cAMP, which then triggers the formation of PK-A (cAMP stimulated protein 
kinase), and eventually leads to the influx of calcium ion by phosphorylation of L-type calcium 
channels. If contraction persists, calcium ions from inside the cells are also released (Klabunde, 
2007).  
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 In figure 2, both endothelin ETA and ETB receptors are also linked to Gq.  This pathway 
triggers the release of intracellular and extracellular Ca
++
 by the activation of phospholipase C 
(PLC). Activation of PLC stimulates the formation of inositol triphosphate (IP3) from 
phosphatidylinositol biphosphate (PIP2).  This increase in IP3 triggers the sacroplasmic reticulum 
in the heart to release calcium ions. However, under normal physiological conditions, voltage-
operating calcium channels do not contribute much to cause muscle contraction. Instead, 
contraction is mediated by the activation of non-selective cation channels. When ET-1 level is 
high, this causes the intercellular free calcium ions to increase. In order to physiologically meet 
the high vasoconstriction necessary of PAH, extracellular calcium ions are released to enter the 
cell (Masaki et al., 1999). 
 Nitric oxide inhibits contraction by decreasing calcium entry through the non-selective 
cation channel.  It is also used to inhibit the intracellular free calcium ion concentration triggered 
by ET-1 binding to its receptors.  In guinea pig tracheal smooth muscle, the use of nifedipine (a 
voltage-operated calcium channel inhibitor) effectively inhibits ETB mediated contraction but not 
ETA mediated contraction. This suggests that there may be another molecular mechanism that 
induces contraction via the ETB receptor (Masaki et al., 1999). 
 
Co-Transmission in the Sympathetic Nervous System 
The sympathetic nervous system innervates many organs and tissues, one of them being 
the vasculature. Larger pulmonary arteries appear to be more richly innervated compared to 
smaller ones (Downing & Lee, 1980). These sympathetic innervations normally control the tone 
and thus pressure of the pulmonary arteries. For example, externally stimulating the upper 
thoracic sympathetic chain, middle cervical ganglia or thoracic vagosympathetic branches with a 
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current consistently raises pulmonary arterial pressure (10-15% over resting pressure) while 
maintaining constant blood flow.  However, when the pulmonary arterial pressure is kept 
constant and flow is allowed to vary, stimulating the same nervous structures elicits a drop in 
blood flow by as much as 30% (Downing & Lee, 1980). Pulmonary arterial pressure is 
controlled by sympathetic neuronal release of neurotransmitters at the vascular neuroeffector 
junction. Specifically, the tone of the arteries is controlled by the noradrenergic neurons, which 
release neurotransmitters towards vascular smooth muscles. For example, arterial tone is 
maintained upon continuous stimulation of noradrenergic neurons releasing norepinephrine 
(NE). Increasing sympathetic stimulation of noradrenergic neurons results in arterial constriction. 
On the other hand, decreasing sympathetic stimulation of noradrenergic neurons results in 
arterial dilation (Craig, 2004). Increased arterial constriction, and thus resistance, is a sign of 
pulmonary arterial hypertension (Pulmonary Arterial Hypertension, 2005). 
In the past, it was thought that postganglionic neurons used only one neurotransmitter. 
However, this has been proven incorrect by evidence obtained from anatomical and 
pharmacological studies.  It is has now been demonstrated that multiple neurotransmitters are 
released by postganglionic neurons at the neuroeffector junctions. Neuropeptides Y, NE, or ATP 
were found upon sympathetic nerve stimulation. Histochemical studies have shown that 
immunoreactive neuropeptides are co-localized with NE, indicating that multiple 
neurotransmittes are released by the sympathetic postganglionic neurons. Additionally, 
neurotransmitters released as a result of sympathetic nervous system stimulation can function as 
co-transmitters, modulators, or co-mediators along with NE (Loewy & Spyer, 1990). 
NE, ATP and NPY are the three main neurotransmitters/ neuromodulators released by 
postganglionic sympathetic nerves (Figure-3) (Sneddon & Burnstock, 1984; Stjarne & Astrand, 
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1986).  Depending on cellular conditions or stimulation frequency, NE, ATP and NPY are co-
released at different proportions in order to better control smooth muscle tone (Kasakov et al., 
1988). 
 
Figure 3: Role of ATP and NE as Neuromodulators.  ATP and NE are 
coreleased from the same vesicle prejunctionally, and they can act as 
neuromodulators. At the postjunction, ATP acts on P2- purinoceptor receptor to 
caused blood vessel contraction, and NE binds to α1- adrenoceptor to prolong 
the contraction. These neurotransmitters can modulate its own release by 
binding to the α2- adrenoceptors and P1 purinoceptors located at the prejunctions 
(Burnstock, 1984) 
 
These neurotransmitters can modulate the release of themselves and each other (Figure-
3). For example, ATP can postjunctionally modulate and enhance the responses of the other co-
transmitters. Prejunctionally, adenosine (ATP's metabolic breakdown product) was shown to 
modulate the release of noradrenaline from peripheral sympathetic nerves in a variety of tissues 
(Burnstock, 2009).  NPY is usually co-stored with ATP and NE, and acts as a neuromodulator by 
prejunctionally reducing the release of NE and ATP, and/or by postjunctionally increasing the 
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response to adrenergic and purinergic components of the sympathetic nervous response (Ellis & 
Burnstock, 1990; Lundberg, 1996). 
Varying stimulation frequency can also modulate neurotransmitters released at the 
neuroeffector junction. Analyzing the kinetics of neuronally released co-transmitters from guinea 
pig vas deferens has shown that ATP and NE are released at different proportions depending on 
electrical frequency. ATP was released at low frequencies (8 HZ) of nerve stimulation. However, 
when stimulated at higher frequencies (16HZ or more), NE was released along with ATP after 
10s of stimulation. It was noted that arterial smooth muscle contracted more at the frequencies in 
which NE was released. These results suggest that ATP and NE could be stored in different 
vesicles (Todorov et al., 1999). 
Additional mechanisms have now been identified that control constriction and 
vasodilatation of arteries; for example, neuromodulators have the ability to alter the release and 
actions of other neurotransmitters. Known neuromodulators include circulating neurohormones, 
prostanoids, bradykinin, histamine, endothelin, in addition to neurotransmitters themselves 
(Milner et al., 1999).  Neurotransmitters released at the neuroeffector junction can be modulated 
by non-neuromediators, such as the vasoactive peptide endothelin ET-1. Prejunctionally, 
endothelin-1 modulates the release of NE to decrease sympathetic neurotransmission. Numerous 
experiments have shown the modulation of sympathetic neurotransmission by ET-1, 6 such 
experiments were performed in the guinea pig pulmonary and femoral arteries (Wiklund & 
Cederqvist, 1989), rat and guinea pig vas deferens (Wiklund et al., 1990), dog coronary artery 
(Aarnio et al., 1993) and rat mesenteric artery (Aarnio et al., 1993). In the rat mesenteric bed, 
ET-1 negatively modulates the release of NPY instead of NE at the neuroeffector junction 
(Hoang et al., 2002).  ET-1 regulates sympathetic neurotransmission postjucntionally by 
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enhancing vasoconstriction caused by both nerve stimulation and a variety of vasoactive agents 
(Henrion & Laher, 1993; Hoang et al., 2002). As ET-1 binds to the ETA receptors, it potentiates 
the postjunctional contractile effects of ATP (Mutafova-Yambolieva & Radomirov, 1993; Hoang 
et al., 2002).   
Hypertension has no single cause, and has been linked to various factors.  Some of these 
factors are structural and functional changes in the vasculature. Medial smooth muscle 
hypertrophy and hyperplasia are all symptoms of hypertension. The three major 
neurotransmitter/ neuromodulators NE, NPY, and ATP in the sympathetic nervous system have 
the ability to trigger a mitogenic response in human vascular smooth muscle cells (Thulin & 
Erlinge, 1995). In the spontaneously hypertensive rat  (SHR) model, ATP was shown to regulate 
vascular smooth muscle cell proliferation (Harper et al., 1998). Other factors include the 
sympathetic nervous system, the rennin-angiotensin system and other endothelial irregularities 
(Milner et al., 1999). Animal models have become particularly useful in mapping the vascular 
changes that lead to the onset of hypertension. The SHR model has become very useful for 
understanding genetically role of hypertension. Using this model it has become possible to look 
at the involvement of the sympathetic nervous system in the origin and continuation of 
hypertension in SHR.  An increase in the density of cerebral artery innervations by sympathetic 
nerves containing NE and NPY was shown to precede the onset of hypertension and related 
medial hypertrophy. After looking at sympathetic neurotransmission in the tail and mesenteric 
arteries of SHRs it has been suggested that ATP plays a greater role in co-transmission than NE.  
So much so, that ATP is the main component of the sympathetic response (Vidal et al., 1986). 
Thus, enhanced sympathetic activity has been implicated in the pathogenesis of hypertension in 
humans. 
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PROJECT PURPOSE 
 
Endothelin has been shown to modulate the release of the neurotransmitters NE and NPY 
at the neuroeffector junction. Previous studies on NGF differentiated PC12 cells suggest that 
ATP levels (a key modulator of vasoconstriction) were modulated by ET-1 (Gardner et al., 
2005).  It was shown that the ETB receptor was able to inhibit the release of ATP by “a specific 
associated G-protein belonging to the Gi/o family, and attenuation of calcium levels” (Gardner et 
al., 2005).  Notably, ATP release is the factor that causes contraction of vascular smooth muscle 
cells, and as a result it also regulates vascular resistance (Mutafova-Yambolieva & Radomirov, 
1993). Therefore, Gardner’s hypothesis states that activation of the ETB receptor by ET-1 
recruits specific receptor associated G-proteins belonging to the Gi/o family, which also 
attenuates calcium levels. The enzymes and proteins involved in the signaling pathway that 
causes the release of ATP are not fully known. Therefore, the objective of this project is to 
identify some of the mediators utilized by the ETB receptor and demonstrate their function in the 
regulation of neurotransmitter release. The knowledge gained from the ETB signaling pathway is 
crucial for the development of a more specific endothelin-targeted therapy for PAH (Gardner, 
2008). 
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METHODS 
 
Cell Culture 
 Undifferentiated rat pheochromocytoma (PC12) cells were obtained from Professor Alice 
Gardner’s lab at the Massachusetts College of Pharmacy and Life Science. After being thawed, 
cells were transferred into T75 flask (polystyrene, Corning, New York) containing growth 
medium [Dulbecco’s Modified Eagle’s Medium (DMEM with 4.5 g/L glucose and 4.0 mM L-
glutamine, Lonza) supplemented with 10% (v/v) horse serum (heat-inactivated at 55°C, 30 min), 
5% (v/v) fetal bovine serum, and a penicillin streptomycin solution (100 U penicillin and 100 g 
streptomycin/mL, Sigma)]. Cells were grown in a NAPCO 5400 series incubator at 37°C, 5.0% 
CO2.  After 24 hours, the cells were differentiated via the addition of mouse nerve growth factor 
(2.5 S NGF, BD Bioscience, 50 ng/mL). Medium was replaced every 2-3 days with growth 
medium containing NGF, as before.  At 80% confluency, cells were subcultured and transferred 
into six well plates (polystyrene, Corning, New York). 
 
Cell Stimulations 
 When cells reached confluence (70%), the growth media were replaced with DMEM 
media (4.5 g/L glucose & 4.0 mM L-glutamine, Lonza) supplemented with mouse NGF (BD 
Bioscience, 50 ng/mL). Cells were serum starved for 24 hours to achieve base line activity. The 
agents used to stimulated cells were BQ 3020 (10 mM; ETB agonist), U73122 (5 µM; PLC 
inhibitor), and KCl (50 mM). The control set was not treated with any of the agents. The first set 
of wells was basal and not stimulated. The second set was stimulated for 5 minutes with KCl. 
The third set was incubated for 5 minutes with BQ3020, and then stimulated for 5 minutes with 
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KCl.  And finally the last set was initially pretreated for 20 minutes with U73122 then incubated 
for 5 minutes with BQ3020, and finally stimulated for 5 minutes with KCl.  All cells were 
incubated in a NAPCO 5400 series incubator.  
 
Preparation of Cell Lysates 
Following stimulation, all media were aspirated, and the cells were washed with 
phosphate-buffered saline (ice-cold 1X PBS, without calcium & magnesium, Cellgrow).  Lysis 
buffer containing 1X RIPA buffer (Pierce, Prod. # 89900) supplemented with 1x Halt Protease 
and phosphatase inhibitor cocktail (Pierce, 100x) was used to lyse cells. All cells were kept on 
ice, and incubated for 15 minutes to facilitate cell lysis. Using a cell scraper and pipetter the 
lysate was removed from each well and placed in a microcentrifuge tube. Inhibitor cocktail (40 
µL) was used to wash each well. The wash from each well was added to the corresponding 
microcentrifuge tube containing cell lysate. This was incubated for 30 minutes. Cell lysate was 
centrifuged at 10,000xg for 10 minutes at 4°C.  The supernatant was collected from each tube. 
The total protein concentration in the supernatant was detrermined by the manufacturer’s 
microplate procedure obtained from the Pierce BCA
TM
 Protein Assay Kit.  Readings were 
obtained from a Synergy HT microplate reader.  The BSA standard curve was made according to 
table 1, in the BCA
TM
 Protein Assay Kit procedure pamphlet from Pierce thermo scientific. A 
modification to the table was made to extend the range of BSA standard concentration curve 
from 2,000 µg/mL – 25 µg/mL, to 2,000 µg/mL - 12.5 µg/mL. 
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Electrophoresis 
Samples were added to Lane Marker Sample Reducing Buffer (Pierce, cat# 3900) at a 
ratio of 1 to 4 to make a 1X solution. The solution was boiled for 5 minutes. The total protein 
from each sample (20 µg), Trichromranger
TM
 Prestain Protein (10 µL), Prosieve®Color Protein 
Marker (Lonza, Cat. No 50550), and Prosieve®Color Protein Marker (10 µL; Cambrex, Cat. No 
50552) were loaded into PAGE® Gold Precast Gel (Lonza, 4-20% Tris-Glycine polyacrylamide 
Gel).  Initially the gels were run in electrophoresis buffer (Pierce, 25 mM Tris, 192 mM glycine, 
0.1% SDS, pH 8.3) at 125V for 30 minutes, then changed to 200V for the remainder of the run. 
 
Immunoblots 
Proteins were transferred onto PVDF membrane (BioTrace
TM
 PVDF Polyvinylidene 
Floride Transfer membrane 0.45 µM, Pall Corporation Life Science) at 100 V for 1 hour or 30V 
overnight in transfer buffer (25 mM Tris, 192 mM glycine, pH 8.0, Pierce) at 4°C.  Memcode
TM
 
Reversible Protein Stain Kit (Pierce) was used to confirm the efficiency of protein transfer. 
Membrane was blocked with Starting Block 
TM
 T20 Blocking buffer (10 mL; Tris buffer saline 
containing 0.05% Tween-20, Pierce) for 30 minutes at 37°C, and then washed with 1X PBS 
(0.1% Tween) for 15 minutes.  
 The antibodies were titrated under different concentrations to determine the optimal band 
contrast. The primary antibody (PLC-β1 rabbit polyclonal IgG, Santa Cruz, 200 µg/mL) was 
diluted 100 and 500 fold with blocking buffer (T20, pierce) up to 10 mL. The membrane was 
then incubated at room temperature for 1 hour with the primary antibody. The secondary 
antibody (Bovine anti–rabbit IgG-HRP, Santa Cruz, 200 µg/0.5 mL) was diluted 500 and 2000 
fold with T20 blocking buffer (Tris buffer saline containing 0.05%Tween-20, Pierce) up to 10 
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mL. The membrane was then incubated at room temperature for 1 hour with the secondary 
antibody following a 15 minute 1X PBS wash (0.1% Tween). Bands of interest were detected 
using chemiluminescence (Pierce® ECL Western Blotting Substrate, Pierce) and analyzed as a 
high-resolution scanned image of the film with the computer NIH program Scion Image. 
 
Immunoprecipitation of Phospholipase C 
Rat PC12 cells (passage number 22) were used for immunoprecipitation. Cells were 
treated with the same agents as before.  Proteins were quantified using a BSA protein assay kit as 
before. The following steps were completed at 4°C. 
Following cell lysis, the supernatant (containing 100 µg of protein) was pre-cleared 
before being used for immunoprecipitation. First, the volume of the lysate was brought up to 1 
mL per vial of solution using 1x RIPA and Halt
TM
 Protease & Phosphatase Inhibitor Cocktail 1X 
(Pierce). To the supernatant control IgG (0.25 µg; normal rabbit IgG, 200 µg/0.5mL, Santa Cruz) 
and suspended agarose conjugate (20 µL; Protein A/G PLUS- Agarose, Santa Cruz) were added 
to each vial. The vials were tumbled using a shaker (model 55 rocking shaker, Midwest 
Scientific) for 30 minutes at 4°C. The supernatant was then collected by centrifuging at 1,000xg 
for 30 seconds. The primary antibody (5 µL; PLC-β1 rabbit polyclonal IgG, Santa Cruz) was 
added to the supernatant and tumbled using the rocking shaker for two hours at 4°C.  Afterwards, 
20 µL of the same protein A/G-agarose was added to the solution and tumbled overnight at 4°C 
under the same conditions as the previous step.  The pellet was collected by centrifuging at 
1,000xg for 30 seconds. The pellet was washed and centrifuged (1,000xg for 30 seconds) three 
times using RIPA buffer (300 µL; Pierce) each wash. On the final wash, the resuspended pellet 
solution was centrifuged under the same conditions as before. The pellet was collected. The 
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beads were resuspended in electrophoresis sample buffer (2x, 40 µL; ProTrack
TM 
Loading buffer 
Lonza; DTT 0.1 M Invitrogen, and 50 mM Tris-HCl 1% SDS). The samples were boiled for 3 
minutes, and centrifuged at 1000xg for 30 seconds. The supernatant (40 µL) was collected from 
each tube, subdivided into two 20 µL aliquots, and stored at -80°C. 
 
Western-blot of Immunoprecipitated Phospholipase C 
The samples (20 µL) and marker (Prosieve® Color Protein Marker, Lonza, Cat. No. 
50550) were loaded into 8-16% Precise 
TM
 Protein SDS-PAGE gels (Prod. No. 25203). The gel 
was run at 125 V in BupH
TM 
 Tris-HEPES-SDS running buffer (100 mM Tris, 100 mM HEPES 
and 3 mM SDS at pH 3±0.5, Pierce) at 4°C. The proteins were transferred onto PVDF membrane 
(BioTrace
TM
 PVDF Polyvinylidene Floride Transfer membrane 0.45 µM, Pall Corporation Life 
Science) at 30V overnight in transfer buffer (25 mM Tris, 192 mM glycine, pH 8.0, Pierce) at 
4°C.  
 The PVDF membrane was blocked with Starting Block 
TM
 T20 Blocking buffer (10 mL; 
Tris buffer saline containing 0.05%Tween-20, Pierce) for 30 minutes at room temperature on a 
rocking machine (Jahre Garentie, Heidolph Rotamax 120). Anti-Phosphotyrosine (4G10
®
) HRP 
Conjugated monoclonal antibody (Millipore, Cat# 16105) was diluted 1:1000 using the Starting 
Block 
TM
 T20 Blocking buffer. The PVDF membrane was incubated in the antibody at 4°C 
overnight on the rocking machine.  The PVDF membrane was washed twice with water, then 
T20 blocking buffer for 5 minutes and finally with water 5 times. The bands were detected 
according to the previous method. 
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Quantifying ATP Release 
 Cells were grown and differentiated as before. On the day of the experiment the media 
was replaced with Krebs’ buffer (1.5 mL per well) composed of NaCl (119 mM), KCl (2.5 mM), 
MgSO4 (1.3 mM), CaCl2 (2.5 mM), NaH2PO4 (1.0 mM), NaHCO3 (26.2 mM), and HEPES (10 
mM) at pH 7.4. The plates were allowed to equilibrate in a shaking water bath at 37°C for 15 
minutes. Cells were stimulated with BQ 3020 (10 mM; ETB agonist), ET-1 (10
-10
 M), U73122 (5 
µM; PLC inhibitor), and KCl (50 mM) in the same manner as before. ET-1 (10
-10
 M) was 
stimulated in a similar way as BQ 3020 (10 mM; ETB agonist). After stimulation, plates were 
placed on ice. The buffer and cells were removed from plates as before, and centrifuged at 1000 
rpm for 2 min. The supernatant was used for quantifying ATP (Gardner et al., 2005). 
 
Analysis of Purines 
 The following method used to analyze purines was described by (Levitt et al., 1984). 
Chloroacetaldehyde was synthesized according to the methods described by (JA et al., 1972). 
This compound was used to form fluorescent 1, N6-ethenopurne analogs (E-purine). E-purines 
can be “simultaneously separated from the sample by reverse-phase HPLC and quantified by 
fluorescent detection “ (Gardner et al., 2005). Chloroacetaldehyde (50 uL) was incubated with 
the supernatant (from quantifying ATP release) at 80°C for 40 minutes in a dry bath. Placing the 
samples on ice stopped the reaction. Afterwards, the samples were analyzed by HPLC-
fluorometric detection. The different purine analogs formed were separated by a reverse-phase 
C-18 column. Two different buffers were used to create a dual buffer gradient system which 
could be used to separate and elute the purines from the column. Buffer A was composed of 
phosphate buffer (0.1 M, pH 6.0) and buffer B was composed of 75% 0.1M phosphate buffer and 
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25% methanol at pH 6.0. The dual buffer gradient system was created by gradually increasing 
the concentration of buffer B while decreasing the concentration of buffer A.  A Varian 9070 
Fluorescence Detector was set at an excitation wavelength of 300nm, and an emission 
wavelength of 420 nm, in order to detect the fluorescent purine derivatives.  Carrying out a 
comparison against purine standard retention times identified the purine peaks. The purine 
content of the sample was quantified using the Varian Star Workstation Software to integrate the 
purine peaks. “ATP analysis was performed on perfusates and normalized against protein 
concentrations” (Gardner et al., 2005). 
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RESULTS 
 
 NGF-differentiated PC12 cells were used in this study of the signaling mechanism 
utilized by the endothelin-1 (ET-1) modulation of sympathetic neurotransmission. Since ET-1 is 
an important vasomodulating hormone, understanding its mechanism of action is important for 
designing drugs to treat hypertension diseases.  Analyzing the signaling pathway of the ETB 
receptor has given insight into its role in pulmonary arterial hypertension (PAH).  It was 
previously shown that ET-1 binding to the ETA receptor resulted in phosphorylation of PLC, 
which caused the levels of 1,4,5-triphosphate (IP3) and diacyglycerol to increase (Senogles, 
1994).  This increased level of IP3 in turn caused the intracellular calcium concentration to 
increase.  In smooth muscle, studying the ET-1 pathway revealed that phosphorylation of PLC 
caused intracellular calcium to increase transiently (Takuwa, 1990).  In this project, treatment of 
PC12 cells with PLC inhibitors, or ET-1, or other ETB agonists were used to test whether PLC 
kinase plays a role in ETB-mediated inhibition of ATP release.  
 
Phospholipase C Modulates Endothelin-Mediated ATP Release Via the ETB Receptor  
 In order to determine whether phospholipase C (PLC) modulates the release of ATP from 
PC12 cells, the effects of a PLC antagonist on the K
+
 evoked release of ATP from NGF-
differentiated PC12 cells were studied to show whether this agent could reverse the ET-1 
induced inhibition on the K
+
 evoked release of ATP (Figure-4). Stimulation of NGF 
differentiated PC12 cells with KCl (50 mM) (first histobar) caused ATP to release over basal 
levels.  Adding ET-1 (second histobar) reduced ATP levels. The addition of the PLC inhibitor 
(U73122, shown as U7 in the figure) (third histobar) reversed the ET-1-induced inhibition on the 
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K
+
 evoked release of ATP; however, the changes in ATP levels were not significant. Thus, this 
data shows that in PC12 cells, ET-1 may act to lower KCl-induced ATP release, and this release 
appears to require PLC. 
 
 
Figure 4: The Effect of ETA/B Agonist ET-1 and Phospholipase C Inhibition 
on Stimulated KCl Induced ATP Release.   Undifferentiated  rat pheochromo-
cytoma (PC12) cells were grown to 70-80% confluency and were differentiated 
by mouse NGF (50 ng/mL). Cells were serum starved for 24 hours and were 
stimulated with U73122 (5µM), ET-1 (10-10 M), or KCl (50 mM) accordingly. 
Treatment with the ETA/B agonist ET-1 reduced ATP levels compared to KCL-
stimulated ATP release. While in the presence of U73122, ET-1 modulated 
KCL-stimulation increased ATP release. Both of these changes were non-
significant.  Values are shown relative to untreated samples.  Histobars denote 
the mean of 3 experiments.  Error bars denote standard error. 
 
 
 
 Because ET-1 binds with equal affinity to the ETA and the ETB receptors, the effect of the 
ETB receptor by itself on PLC activation could not be clearly delineated.  Therefore, the ETB 
agonist (BQ3020) was tested in conjunction with the U7 PLC inhibitor to further elucidate the 
role of PLC in ATP release mediated by the ETB receptor (Figure-5).  NGF-differentiated PC 12 
cells were stimulated with KCl (50 mM) to evoke ATP release above basal level (first histobar). 
The ATP levels decreased 30.7% under the presence of the ETB receptor agonist BQ3020 
(second histobar).  The PLC inhibitor U73122 reversed this inhibition by evoking a 73.5% 
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increased in ATP release (third histobar).  Thus, receptor ETB indeed appears to participate in the 
lowering of KCL-induced ATP release. 
 
 
 
 
Figure 5: The Effect of ETB Agonist and Phospholipase C Inhibition on KCl 
Induced ATP Release. Undifferentiated rat pheochromocytoma (PC12) cells 
were grown to 70-80% confluency and were differentiated by mouse NGF (50 
ng/mL). Cells were serum starved for 24 hours and were stimulated with 
U73122 (5 µM), BQ 3020 (10 mM), or KCl (50 mM) accordingly. After 
stimulation  with KCl, ATP levels decreased (30.7%, p<0.05) under the 
presence of the ETB receptor agonist, BQ-3020, compared to KCl stimulation 
only. The inhibitory effects of BQ-3020 on ATP release was reversed after 
pretreating with the non-specific PLC inhibitor U73122 (73.5% increase, 
p<0.05). Each bar represents the mean ±S.E.M of 12 to 15 from six individual 
experiments. *, P< 0.05 KCl vs. KCl+ BQ3020 and KCl+ BQ3020 vs. KCl 
+BQ3020 +U73122.  Error bars denote standard error. 
 
 
 In order to determine whether PLC plays a significant role in modulating basal ATP 
release, BQ 3020 or U73122 were incubated with control cells (Figure-6).  The BQ3020 (shown 
as BQ in the figure) ETB agonist (second histobar) had no significant impact on basal ATP 
levels.  However, the addition of the U73122 PLC-inhibitor (third histobar) resulted in a 
significant increase in the basal level of ATP release, suggesting that PLC plays a role in 
modulating basal neurotransmitter release. 
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Figure 6: The Effect of ETB Agonist and Phospholipase C Inhibitor on 
Basal ATP Release.  Undifferentiated rat pheochromocytoma (PC12) cells were 
grown to 70-80% confluency and were differentiated by mouse NGF (50 
ng/mL).  Cells were serum starved for 24 hours and were incubated in either BQ 
3020 (10 mM; 5 min) or U73122 (5 µM; 20 min). The BQ ETB agonist (second 
histobar) did not have a significant impact on basal ATP level, but inhibiting 
PLC with U7 significantly increased ATP release (third histobar). Therefore, 
PLC significantly modulates basal ATP release. Each bar represents the mean 
±S.E.M of 12 to 15 from six individual experiments. *, P< 0.05 Basal + BQ3020 
vs. Basal + U73122.  Error bars denote standard error. 
 
Quantifying PLC Phosphorylation Via Western Blotting 
 After determining that PLC plays a role in ATP release, it became important to figure out 
which PLC family and isotype takes part in the ETB signal transduction pathway. U73122 has 
been shown to only inhibit PLC- and PLC- (Heemskerk et al., 1997). PLC- was chosen over 
other PLC family members because it is involved in the IP3 pathway.  Cellular levels of PLC-β 
were monitored by immunoblot (Figure-7).  For each lane there was only one PLC-1 band 
instead of a doublet, as one would expect from a phosphorylated enzyme in a western blot. The 
primary antibody (in the immunoblots section under methods) is capable of detecting both 
phosphorylated and unphosphorylated PLC-1. The phosphorylated PLC-1 should appear as a 
slightly heavier band above the unphosphorylated band. Because this assay was not sensitive 
enough, a doublet was not seen. 
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Figure 7: The Effect of ETB Agonist (BQ3020) on PLC Phosphorylation. 
Undifferentiated rat pheochromocytoma (PC12) cells were grown to 70-80% 
confluency and were differentiated by mouse NGF (50 ng/mL). Cells were 
serum starved for 24 hours and were stimulated with BQ 3020 (10 mM), and 
KCl (50 mM) as listed. Primary antibody detection (5 µL; PLC-β1 rabbit 
polyclonal IgG, Santa Cruz diluted 1:500 in Tris buffer saline containing 
0.05%Tween-20, Pierce) and secondary antibody (Bovine anti –rabbit IgG-HRP, 
Santa Cruz, 200µg/0.5 mL: diluted 1:2000 in Tris buffer saline containing 
0.05%Tween-20, Pierce).   
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DISCUSSION 
 
 In the sympathetic nervous system, endothelin-1 (ET-1) was previously shown to act as a 
neuromodulator in experiments done on the guinea pig pulmonary and femoral arteries (Wiklund 
& Cederqvist, 1989), rat and guinea pig vas deferens (Wiklund et al., 1990), dog coronary artery 
(Aarnio et al., 1993) and rat mesenteric artery (Aarnio et al., 1993).  Specifically, when studying 
the effects of ET-1 on the endothelial ETA receptor, ET-1 was shown to potentiate the 
postjunctional contractile effects of ATP (Mutafova-Yambolieva & Radomirov, 1993; Hoang et 
al., 2002). Notably, ATP release is the factor that causes contraction of vascular smooth muscle 
cells, and as a result regulates vascular resistance (Mutafova-Yambolieva & Radomirov, 1993).  
So understanding this pathway is important for the future design of drugs to treat hypertension 
disorders. 
 Previous data showed that the ETB receptor was able to inhibit the release of ATP by “a 
specific associated G-protein belonging to the Gi/o family, and attenuation of calcium levels” 
(Gardner et al., 2005).  Calcium therefore plays an essential role in neurotransmitter release. As 
previously discussed, calcium can enter the neuron via the opening of the voltage dependent 
calcium channels. Neurotransmitter release can also be altered by modulating calcium release, 
for example by inhibiting voltage-dependent calcium channels by activation of the PLC/Ca(2+)-
dependent PKC signal transduction pathway(Salgado et al., 2007). 
 The Activation of the PLC/Ca(2+)-dependent PKC signal transduction pathway leads to 
PLC phosphorylation which in turn hydrolyzes PIP2 to produce IP3 and diacyglycerol (Hou et al., 
2003). Furthermore, studying the endothelin pathway in smooth muscle revealed that 
phosphorylation of PLC caused intracellular calcium to increase transiently (Takuwa, 1990).   
 34 
 In our project, PLC inhibitors were used to test whether PLC plays a role in ETB 
mediated inhibition of ATP release. Cells were stimulated with the non-specific PLC inhibitor 
(U73122), ETB agonist (BQ3020), and/or KCl. When the ETB agonist BQ3020 bound to the ETB 
receptor, a decrease in ATP levels was observed.  However, once the non-specific PLC inhibitor 
U73211 inhibited PLC, an increase in ATP levels was seen. KCl stimulation of ATP in the 
presence or absence of U73122 did not change ATP levels. This suggested that PLC plays a role 
in the ETB signal transduction pathway because it did not alter KCl-induced ATP levels. 
Moreover, KCl caused ATP levels to increase by acting on voltage gated calcium channels. 
However, under basal conditions, ATP levels of cells that were challenged with ETB agonists 
only slightly decreased, whereas those that were treated with U73122 caused ATP levels to 
increase significantly. Therefore, PLC plays a role in modulating basal and ETB-modulated ATP 
release. 
 U73122 has been previously used extensively as a PLC inhibitor in the study of cellular 
signal transduction (Wilsher, et al., 2007).  However, this aminosteroid is not entirely specific to 
any PLC family but has been shown to inhibit both PLC-β and PLC-γ isoforms, but not other 
PLC families (delta, epsilon, zeta and eta) (Heemskerk et al., 1997). Furthermore, U73122 has 
been shown to have a higher affinity towards human PLC-β2 compared to the other PLC-β 
isoforms (PLC-β1, PLC-β3, and PLC-β4), although this specificity has not been confirmed with 
the rat PLC-β analyzed in our project (Hou et al., 2003). 
 The first PLC immunoblot did not show a doublet around 150 kD (Figure-7), as one 
would expect when detecting both phosphorylated and unphorphorylated PLC.  The antibody 
used in our immunoblot is capable of detecting both forms.  Since only a small portion of PLC 
gets phosphorylated during activation, we conclude that the immunoblot method was not 
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sensitive enough to detect the phosphorylated form.  PLC phosphorylation occurs within the first 
few signaling cascading events, is transient, and is not heavily amplified, so the phosphorylated 
form exists at very low concentrations, making it difficult to detect by this method (Hou et al., 
2003).  
 In order to enhance the sensitivity, an immunoprecipitation using PLC-1 antibody 
followed by an immunoblot with phosphotyrosine antibody was performed.  In this method, only 
phosphorylated PLC is detected (by the phosphotyrosine antibody), thus only one band around 
150 kD would be expected in the blot.  However, because of ongoing troubleshooting, this result 
is still pending.  If the phosphorylation levels were to correspond to ATP levels, then one could 
conclude that PLC activation is involved in ETB signal transduction. 
 If a decrease in ATP levels, upon ETB stimulation, is not found to correspond to a 
decrease in PLC phosphorylation, then the following conclusions could be made. Firstly, the blot 
could again not be sensitive enough, and further study would be needed to develop a more 
sensitive assay (radio-nucleotide assay using 
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P would be employed).  Secondly it could be that 
PLC-1 does not take part in the rat NGF differentiated PC12 ETB pathway.  Finally it could be 
that PLC-1 is phosphorylated by serine (Ryu, et al., 1990) as shown in other cellular PLC signal 
transduction.  Eukaryotic kinases in addition to phosphorylating tyrosine residues can also 
phosphorylate serine/threonine motifs, but very rarely histidine and aspartate amino acid residues 
(IonSource, 2009).  As this project focused solely on tyrosine phosphorylation of PLC-1 an 
assay looking for serine/threonine phosphorylation would need to be undertaken.  Therefore, the 
short-term goal of this project is to improve quantification of PLC-1 phosphorylation. 
 Future directions would be to develop a PLC-knockdown protocol to determine whether a 
relationship exists between PLC-1 phosphorylation and ATP release to support this assertion. 
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